In premenopausal women with non-metastatic breast cancer, use of tamoxifen may nearly double the risk of endometrial cancer, researchers report.

Adding tucatinib to first-line maintenance therapy with trastuzumab/pertuzumab extends PFS for patients with previously-treated HER2+ metastatic breast cancer.

Pooled data from 3 phase III clinical trial shows that the addition of neoadjuvant carboplatin to chemotherapy improves outcomes for patients with early-stage triple-negative breast cancer.

In patients with triple-negative breast cancer who have received neoadjuvant chemotherapy, testing for Ki67 and TILs has prognostic value.

Investigators sought to identify a relationship between cruciferous vegetable intake and breast cancer risk in the Nurses’ Health Study (NHS) and NHSII.